Bessemer Group Inc. reduced its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 17.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,739 shares of the medical equipment provider’s stock after selling 811 shares during the quarter. Bessemer Group Inc.’s holdings in Zimmer Biomet were worth $491,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Zimmer Biomet by 5,200.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 988 shares during the last quarter. Azimuth Capital Management LLC bought a new stake in Zimmer Biomet during the 2nd quarter valued at $201,000. Aries Wealth Management bought a new stake in Zimmer Biomet during the 2nd quarter valued at $202,000. HighPoint Advisor Group LLC bought a new stake in Zimmer Biomet during the 3rd quarter valued at $202,000. Finally, Donaldson Capital Management LLC bought a new stake in Zimmer Biomet during the 3rd quarter valued at $205,000. Institutional investors own 87.10% of the company’s stock.

Shares of NYSE ZBH opened at $112.69 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.89 and a quick ratio of 0.96. Zimmer Biomet Holdings Inc has a 12 month low of $104.28 and a 12 month high of $134.55. The firm has a market capitalization of $23.15 billion, a price-to-earnings ratio of 14.03, a P/E/G ratio of 2.30 and a beta of 1.16.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Friday, October 26th. The medical equipment provider reported $1.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.03. The business had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.72 EPS. Equities research analysts expect that Zimmer Biomet Holdings Inc will post 7.65 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s payout ratio is 11.96%.

A number of research firms recently commented on ZBH. Needham & Company LLC upped their price target on shares of Zimmer Biomet from $146.00 to $150.00 and gave the company a “strong-buy” rating in a report on Monday, July 30th. Cantor Fitzgerald reiterated a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet in a report on Monday, August 27th. Piper Jaffray Companies upped their price target on shares of Zimmer Biomet from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Monday, July 30th. BTIG Research started coverage on shares of Zimmer Biomet in a report on Thursday, August 16th. They issued a “neutral” rating for the company. Finally, JMP Securities upped their price objective on shares of Zimmer Biomet from $133.00 to $140.00 and gave the stock an “outperform” rating in a report on Monday, July 30th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $134.63.

In related news, VP Chad F. Phipps sold 30,100 shares of the stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $132.37, for a total value of $3,984,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bryan C. Hanson purchased 410 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The stock was acquired at an average price of $123.03 per share, with a total value of $50,442.30. Following the completion of the purchase, the chief executive officer now owns 25,487 shares in the company, valued at $3,135,665.61. The disclosure for this purchase can be found here. 0.71% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2018/11/22/zimmer-biomet-holdings-inc-zbh-position-reduced-by-bessemer-group-inc.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: What is insider trading?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.